Latest Eisai News & Updates

See the latest news and media coverage for Eisai. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eisai

Human health care pharmaceutical company

eisai.com

Headquarters: Bunkyo-Ku, Japan
Company type: Public company
Number of employees: 1,000–5,000
Industry: Pharmaceuticals

Last updated October 20

Latest news about Eisai

In short: Eisai reported strong Leqembi sales growth, new subcutaneous approvals, and a ¥1 trillion revenue target.

Company announcements

April 3 Eisai

Eisai opens new Global Capability Centre

The IT hub in Visakhapatnam, India, standardizes global IT operations and drives digital transformation. An opening ceremony celebrated its launch.

February 20 Eisai

Eisai receives human capital awards for third year

Eisai earns 'Thought Leaders of Human Capital 2025' and 'Human Capital Management Excellence 2025 Gold Award' for excellent management and disclosure.

January 26 Eisai

Eisai announces FDA acceptance of LEQEMBI IQLIK sBLA

The application for subcutaneous starting dose in early Alzheimer’s is under priority review with action date May 24, 2026.

January 21 Eisai

Eisai ranks 36th in Global 100 sustainability list

It marks Eisai's tenth inclusion and highest rank among global pharmaceutical companies. Evaluation based on UN SDGs, sustainable revenue, and investment.

Media coverage

October 20 Marketscreener

Eisai Co., Ltd. Stock Exchange

17/09 Japan approves Eisai's LEQEMBI pen as a new subcutaneous treatment method for Alzheimer's MT 16/09 BioArctic AB and Eisai announce approval of the subcutaneous Leqembi pen...

September 24 Nikkei

Eisai and Merck & Co., combination therapy of "Lenvima" and "Verquvo" ...

[Press Release] Announcement Date: September 28, 2026 Regarding the combination therapy of "Lenvima (R)" (lenvatinib) and "Verquvo (R)" (belzutifan), the U.S. FDA has approved it for adult patients with advanced clear cell renal cell carcinoma (ccRCC) who have prior treatment history. For patients with advanced ccRCC who have a history of treatment with PD-1/PD-L1 inhibitors, a clinical trial comparing the combination therapy of "Lenvima" and "Verquvo" to cabozantinib was conducted...

September 16 Nikkei

Eisai's Alzheimer's drug "lecanemab" subcutaneous injection approved in Japan

Eisai and US biopharmaceutical company Biogen announced on the 16th that they have obtained approval for the manufacture and sale in Japan of a subcutaneous formulation of "lecanemab (product name Leqembi)," an Alzheimer's disease treatment drug, which can be administered in a short time. It is possible to administer at home, and it is expected to reduce the burden on patients and caregivers. The subcutaneous formulation is administered once a week using a dedicated pen-type injector...

September 3 RTTNews

Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease

Drug makers Biogen Inc. ( BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK,4523.T,EII.SG) announced Wednesday that Japan has approved LEQEMBI Pen, the subcutaneous (SC) formulation of...

Never miss news about Eisai

Track Eisai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eisai competitors & trending companies

Browse news for competitors to Eisai and other trending companies.